Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

P304: Patients with perianal Crohn’s disease have poor disease outcomes after primary bowel resectionECCO '16 Amsterdam

Year: 2016

Authors:

Y. M. Han*¹, J. W. Kim², J. H. Kim¹, S.-J. Koh², H. Yoon³, C. Lee⁴, J. P. Im¹, J. S. Kim¹

¹Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, ²Seoul National University Boramae Hospital, Department of Internal Medicine, Seoul, South Korea, ³Seoul National University Bundang Hospital, Departments of Internal Medicine, Seongnam, South Korea, ⁴Healthcare System Gangnam Centre, Seoul National University Hospital, Department of Internal Medicine, Division of Gastroenterology, Seoul, South Korea

P305: No increased risk for infections with thiopurine-induced leukopenia in inflammatory bowel disease patients without a variant in thiopurine S-methyltransferaseECCO '16 Amsterdam

Year: 2016

Authors:

M. Broekman*¹, M. Coenen², C. van Marrewijk², G. Wanten¹, L. Derijks³, S. Vermeulen^{2, 4}, D. Wong⁵, O. Klungel⁶, A. Verbeek⁴, P. Hooymans⁵, H. Scheffer², H.-J. Guchelaar⁷, D. de Jong¹

¹Radboud University Medical Centre, Department of Gastroenterology, Nijmegen, Netherlands, ²Radboud University Medical Centre, Department of Human Genetics, Nijmegen, Netherlands, ³Maxima Medical Centre Loc. Veldhoven, Department of Gastroenterology and Hepatology, Veldhoven, Netherlands, ⁴Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, Netherlands, ⁵Zuyderland Medical Centre, Department of Clinical Pharmacy, Pharmacology and Toxicology, Sittard, Netherlands, ⁶Utrecht University, Departement of Pharmacoepidemiology and Clinical Pharmacotherapy, Utrecht, Netherlands, ⁷Leiden University Medical Centre, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

P306: The real-life experience of vedolizumab efficacy and safety in ulcerative colitis: a prospective observational multicentre cohort studyECCO '16 Amsterdam

Year: 2016

Authors:

A. Amiot*¹, L. Peyrin-Biroulet², C. Stefanescu³, J. C. Grimaud⁴, J. Filippi⁵, B. Pariente⁶, X. Roblin⁷, R. Altwegg⁸, D. Laharie⁹, P. Marteau¹⁰, A. Buisson¹¹, C. Trang-Poisson¹², S. Nancey¹³, G. Savoye¹⁴, S. Viennot¹⁵, H. Brixi-Benmansour¹⁶, F. Carbonnel¹⁷, Y. Bouhnik³

¹Henri Mondor Hospital, Gastroenterology, Creteil, France, ²CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, ³APHP Beaujon, Department of Gastroenterology, Clichy, France, ⁴Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, ⁵Archet 2 Hospital, Department of Gastroenterology, Nice, France, ⁶CHRU Lille, Department of Gastroenterology, Lille, France, ⁷University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, ⁸CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, ⁹CHU Bordeaux, Department of Gastroenterology, Bordeaux, France, ¹⁰Hospital Lariboisière, Department of Gastroenterology, Paris, France, ¹¹CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, ¹²CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, ¹³Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, ¹⁴CHU Rouen, Department of Gastroenterology, Rouen, France, ¹⁵Hospital Cote de Nacre, Department of Gastroenterology, Caen Cede, France, ¹⁶Robert Debre Hospital, Department of Gastroenterology, Reims, France, ¹⁷CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France

P307: Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extensionECCO '16 Amsterdam

Year: 2016

Authors:

W. Reinisch*¹, P. Gibson², W. J. Sandborn³, B. Feagan⁴, C. Marano⁵, R. Strauss⁵, J. Johanns⁵, H. Zhang⁵, L. Padgett⁵, O. J. Adedokun⁵, J.-F. Colombel⁶, J. Collins⁷, P. Rutgeerts⁸, D. Tarabar⁹

¹Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, ²Alfred Hospital, Melbourne, Australia, ³University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, ⁴Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, ⁵Janssen R & D, LLC, Spring House, Pennsylvania, United States, ⁶Mount Sinai, Icahn School of Medicine, New York, New York, United States, ⁷Oregon Health Sciences University, Department of Gastroenterology, Portland, Oregon, United States, ⁸University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, ⁹Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia

P308: Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseasesECCO '16 Amsterdam

Year: 2016

Authors:

Z. Kurti*¹, Z. Vegh¹, M. Rutka², L. Gonczi¹, K. Farkas², K. Gecse¹, P. A. Golovics¹, B. Szalay³, T. Molnar², P. Lakatos¹

¹Semmelweis University, First Department of Medicine, Budapest, Hungary, ²University of Szeged, First Department of Medicine, Szeged, Hungary, ³Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

P309: High infliximab trough levels are associated with better control of inflammation in inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

D. Drobne*¹, T. Kurent¹, P. Rajar², M. Slak³, M. Kozelj¹, G. Novak¹, N. Smrekar¹, S. Plut¹, A. Smid¹, J. Osredkar⁴, B. Stabuc¹, I. Ferkolj¹

¹University Medical Centre Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia, ²University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, ³Faculty of Pharmacy, Ljubljana, Slovenia, ⁴University Medical Centre Ljubljana, Clinical Institute of clinical chemistry and biochemistry, Ljubljana, Slovenia

P310: Patient-reported quality of life during golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom: results from the GO-COLITIS studyECCO '16 Amsterdam

Year: 2016

Authors:

P. Irving*¹, C. Probert², D. R. Gaya³, P. J. Hamlin⁴, S. Sebastian⁵, G. Gillespie⁶, H. Tate⁶, C. Wheeler⁶

¹Guy’s and St Thomas’ Hospitals, London, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁴Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁵Hull & East Yorkshire NHS Trust, Hull, United Kingdom, ⁶MSD UK, Hoddesdon, United Kingdom

P311: No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term resultsECCO '16 Amsterdam

Year: 2016

Authors:

K. Malickova¹, D. Duricova*², M. Kolar², M. Bortlik², V. Hruba², N. Machkova², K. Mitrova², M. Lukas Jr.², M. Lukas²

¹First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, ²ISCARE, IBD clinical and research centre, Prague, Czech Republic

P312: Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey amongst ECCO membersECCO '16 Amsterdam

Year: 2016

Authors:

S. Danese*^{1, 2}, G. Fiorino¹, P. Michetti³

¹Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, ²Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy, ³Clinique La Source-Beaulieu, Crohn and Colitis Centre, Lausanne, Switzerland

P313: Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

M. Choy*^{1, 2, 3}, D. Seah^{1, 3}, A. Gorelik⁴, F. Macrae⁵, M. Sparrow⁶, W. R. Connell², G. Moore⁷, D. Van Langenberg⁸, P. De Cruz^{1, 3}

¹Austin Health, Department of Gastroenterology, Melbourne, Australia, ²St Vincent’s Hospital, Department of Gastroenterology, Melbourne, Australia, ³University of Melbourne, Department of Medicine, Melbourne, Australia, ⁴Royal Melbourne Hospital, Melbourne EpiCentre, Melbourne, Australia, ⁵Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, ⁶The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, ⁷Monash Health, Department of Gastroenterology, Melbourne, Australia, ⁸Eastern Health, Department of Gastroenterology, Melbourne, Australia

P314: Proposal for an anti-tumour necrosis factor–exit strategy based on trough serum levelECCO '16 Amsterdam

Year: 2016

Authors:

U. Helwig*¹, F. Lutter¹, N. Koppka², S. Schreiber³

¹University of Kiel, Medical Practice for Internal Medicine, Oldenburg, Germany, ²Medical Practice for Internal Medicine, Oldenburg, Germany, ³Department of Internal Medicine I - Gastroenterology, Hepatology, Nutrition and Geriatric Medicine, University Hospital Schleswig-Holstein, campus Kiel, Kiel, Germany

P315: Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN studyECCO '16 Amsterdam

Year: 2016

Authors:

P. Michetti*¹, L. Peyrin-Biroulet², M. S. Silverberg³, E. Louis⁴, J. Weinman⁵, J. Sommer⁶, J. Petersson⁷, B. Pappalardo⁷, P. Nurwakagari⁸

¹IBD Centre La Source-Beaulieu, Lausanne, Switzerland, ²Inserm U954 and Department of Gastroenterology, Université de Lorraine, Vandoeuvre-les-Nancy, France, ³Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁴CHU de Liège et Université de Liège, Liège, Belgium, ⁵Institute of Pharmaceutical Sciences & Institute of Psychiatry, King’s College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Inc., North Chicago, Illinois, United States, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

P316: Prognosis of patients with inflammatory bowel disease in clinical remission after de-escalation of infliximab maintenance therapy from 8 to 12 weeksECCO '16 Amsterdam

Year: 2016

Authors:

J. M. Vázquez-Morón, B. Benítez-Rodríguez*, H. Pallarés-Manrique, M. Ramos-Lora

Hospital General Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain

P317: Health care costs associated with standard inflammatory bowel disease care in Australia and opportunities to improve care: a tertiary centre studyECCO '16 Amsterdam

Year: 2016

Authors:

B. Jackson*¹, R. Ma¹, A. Gorelik², D. Con¹, D. Liew², P. De Cruz¹

¹Austin Health, Gastroenterology, Melbourne, Australia, ²Melbourne Health, Melbourne, Australia

P318: Does anti-tumour necrosis factor therapy decrease the risk of initial intestinal resection after the diagnosis of Crohn’s disease? A retrospective single-centre studyECCO '16 Amsterdam

Year: 2016

Authors:

Y. Nagata*¹, M. Esaki¹, A. Hirano¹, J. Umeno¹, Y. Maehata¹, T. Torisu¹, T. Moriyama¹, T. Matsumoto², T. Kitazono¹

¹Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, ²School of Medicine, Iwate Medical University, Division of Gastroenterology, Department of Internal Medicine, Morioka, Japan

P319: Combining anti-inflammatory treatment with antiviral treatment in severe cytomegalovirus-positive ulcerative colitis does not affect colectomy rate: a retrospective European multicentre studyECCO '16 Amsterdam

Year: 2016

Authors:

U. Kopylov*¹, K. Papamichael^{2, 3}, K. Katsanos⁴, M. Waterman⁵, A. Bar-Gil Shitrit⁶, T. Boysen⁷, F. Portela⁸, A. Peixoto⁹, A. Szilagyi¹⁰, M. Silva⁹, G. Maconi¹¹, O. Har-Noy¹, P. Bossuyt¹², G. Mantzaris², M. Barreiro de Acosta¹³, M. Chaparro¹⁴, D. Christodoulou⁴, R. Eliakim¹, J.-F. Rahier¹⁵, F. Magro⁹, S. Ben-Horin¹⁶, X. Roblin¹⁷

¹Sheba Medical Centre, Gastroenterology, Tel Hashomer, Israel, ²Evaggelismos Hospital, Gastroenterology, Athens, Greece, ³KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ⁴University of Ioannina, Gastroenterology, Ioannina, Greece, ⁵Rambam Healthcare Campus, Gastroenterology, Haifa, Israel, ⁶Shaare Zedek Medical Centre, Digestive diseases Institute, Jerusalem, Israel, ⁷Herlev University Hospital, Gastroenterology, Herlev, Denmark, ⁸Hospital Universidade Coimbra, Gastroenterology, Coimbra, Portugal, ⁹Centro Hospitalar São João, Gastroenterology, Porto, Portugal, ¹⁰Jewish General Hospital, Department of Gastroenterology, Montreal, Canada, ¹¹Luigi Sacco’ University Hospital, Gastroenterology, Milan, Italy, ¹²Imelda GI clinical research Centre,, Gastroenterology, Bonheiden, Belgium, ¹³University Hospital of Santiago de Compostela, IBD Unit, Gastroenterology Department, Santiago de Compostela, Spain, ¹⁴Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, ¹⁵CHU Dinant Godinne, UCL Namur, Gastroenterology, Yvoir, Belgium, ¹⁶Chaim Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel, ¹⁷CHU de Saint-Etienne, Gastroenterology, Saint-Etiennne, France

P320: Clinical and economic effect of short infliximab infusion protocol in patients with inflammatory bowel diseases: a multicentre studyECCO '16 Amsterdam

Year: 2016

Authors:

M. Cappello*¹, G. Costantino², A.C. Privitera³, F. Bossa⁴, A. Lauria⁵, L. Grossi⁶, M. B. Principi⁷, N. Della Valle⁸, M. A. Veneziano⁹, D. Crocchiolo⁹

¹University of Palermo, Gastroenterology Section, DiBiMis, Palermo, Italy, ²Università di Messina, Dipartimento di Medicina Interna e Terapia Medica, Messina, Italy, ³Azienda Ospedaliera per l’Emergenza, Ospedale Cannizzaro, Catania, Gastroenterologia, Catania, Italy, ⁴Casa Sollievo della Sofferenza, Gastroenterologia, S. Giovanni Rotondo, Foggia, Italy, ⁵A. O. Bianchi-Melacrino-Morelli, Reggio Calabria, Gastroenterologia e Endoscopia Digestiva, Reggio Calabria, Italy, ⁶Ospedale Spirito Santo, Pescara, Fisiopatologia Digestiva, Pescara, Italy, ⁷Policlinico, Department of Gastroenterology, Bari, Italy, ⁸Ospedale di Foggia, Gastroenterologia, Foggia, Italy, ⁹MSD Italy, Rome, Italy

P321: Mucosal healing in a cohort of inflammatory bowel diseases paediatric patients in clinical remissionECCO '16 Amsterdam

Year: 2016

Authors:

F. P. Giugliano¹, C. Strisciuglio*², M. Martinelli¹, M. Andreozzi¹, S. Cenni¹, A. Staiano¹, E. Miele¹

¹University Federico II, Department of Translational Medical Science, Section of Paediatrics, Naples, Italy, ²Second University of Naples, Department of Woman, Child and General and Specialised Surgery, Naples, Italy

P322: Complications to parenteral therapy in patients with intestinal failure because of inflammatory bowel disease: A retrospective cohort studyECCO '16 Amsterdam

Year: 2016

Authors:

R. Lorentsen, L. K. Munck, S. Wildt*

Køge University Hospital, and Faculty of Health Sciences, University of Copenhagen, Section of Gastroenterology, Medical Department, Køge, Denmark

P323: Prevalence of vitamin D deficiency in patients with inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

N. Toke*, P. Kakkadasam Ramaswamy, B. Sebastian, S. Mathai, C. Panackel

Medical Trust Hospital, Department of Gastroenterology, Ernakulam, India